Frazier-backed Recida launches with $8.5M series A

Recida Therapeutics Inc. (Menlo Park, Calif.) raised $8.5 million in a series A round led by Frazier Healthcare Partners as it completed a pair of deals involving its lead compound RC-01.

The new company gained rights outside of Japan to RC-01 from Fujifilm Toyama Chemical Co. Ltd. (Tokyo, Japan) and subsequently granted MicuRx Pharmaceuticals Inc. (Foster City, Calif.) rights to develop and commercialize the compound in Greater China. ...